TRACER Europe

TRACER Europe is a pioneering imaging CRO that leverages Phase 0 microdosing and molecular imaging to de-risk and accelerate drug development for biopharma sponsors. Its core service involves labeling a sponsor's drug candidate (antibody, small molecule, peptide, etc.) to visualize and quantify its behavior in human patients at a very early stage, enabling critical go/no-go decisions before costly traditional trials. Founded in 2018, the private company operates in a high-growth niche, helping clients reduce development costs and timelines by providing human proof-of-concept data faster than conventional pathways.

Molecular imaging (nuclear & optical) platform for Phase 0 microdosing studies. Labels drug candidates (antibodies, small molecules, peptides, etc.) with radionuclides or fluorescent dyes to visualize and quantify biodistribution, pharmacokinetics, and target engagement in human patients.

TRACER competes with imaging service groups within large, full-service CROs (e.g., IQVIA, Parexel) and specialized academic medical centers offering molecular imaging. Its differentiation is a dedicated focus on Phase 0 trial design, regulatory strategy, and execution as an integrated imaging CRO.